Eli Lilly’s October 2024 evaluation agreement for Peptron’s SmartDepot sustained-release microsphere platform, later extended through late 2026, keeps the possibility of a commercial license or technology transfer alive and under active review. Trader sentiment remains closely balanced because Lilly’s heavy investment in its oral GLP-1 candidate orforglipron has raised doubts about near-term demand for long-acting injectable depots, while separate reports of Lilly exploring Camurus lipid-gel technology add competitive pressure. No binding commercial deal has been disclosed to date, and the evaluation remains limited to internal R&D use. Key upcoming catalysts include any public readout on SmartDepot performance with Lilly’s peptide candidates, potential extension announcements before the October 7, 2026 cutoff, or statements from Lilly’s business-development team on injectable versus oral obesity priorities.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
NUOVO
NUOVO
7 ott 2026
NUOVO
NUOVO
7 ott 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement for Peptron’s SmartDepot sustained-release microsphere platform, later extended through late 2026, keeps the possibility of a commercial license or technology transfer alive and under active review. Trader sentiment remains closely balanced because Lilly’s heavy investment in its oral GLP-1 candidate orforglipron has raised doubts about near-term demand for long-acting injectable depots, while separate reports of Lilly exploring Camurus lipid-gel technology add competitive pressure. No binding commercial deal has been disclosed to date, and the evaluation remains limited to internal R&D use. Key upcoming catalysts include any public readout on SmartDepot performance with Lilly’s peptide candidates, potential extension announcements before the October 7, 2026 cutoff, or statements from Lilly’s business-development team on injectable versus oral obesity priorities.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercato aperto: May 5, 2026, 8:02 PM ET
Volume
$8,217Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 evaluation agreement for Peptron’s SmartDepot sustained-release microsphere platform, later extended through late 2026, keeps the possibility of a commercial license or technology transfer alive and under active review. Trader sentiment remains closely balanced because Lilly’s heavy investment in its oral GLP-1 candidate orforglipron has raised doubts about near-term demand for long-acting injectable depots, while separate reports of Lilly exploring Camurus lipid-gel technology add competitive pressure. No binding commercial deal has been disclosed to date, and the evaluation remains limited to internal R&D use. Key upcoming catalysts include any public readout on SmartDepot performance with Lilly’s peptide candidates, potential extension announcements before the October 7, 2026 cutoff, or statements from Lilly’s business-development team on injectable versus oral obesity priorities.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$8,217Data di fine
7 ott 2026Mercato aperto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 evaluation agreement for Peptron’s SmartDepot sustained-release microsphere platform, later extended through late 2026, keeps the possibility of a commercial license or technology transfer alive and under active review. Trader sentiment remains closely balanced because Lilly’s heavy investment in its oral GLP-1 candidate orforglipron has raised doubts about near-term demand for long-acting injectable depots, while separate reports of Lilly exploring Camurus lipid-gel technology add competitive pressure. No binding commercial deal has been disclosed to date, and the evaluation remains limited to internal R&D use. Key upcoming catalysts include any public readout on SmartDepot performance with Lilly’s peptide candidates, potential extension announcements before the October 7, 2026 cutoff, or statements from Lilly’s business-development team on injectable versus oral obesity priorities.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti